Development and immunogenicity testing of

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/381732

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This research will advance the development of a novel vaccine strategy based on duck hepatitis B virus-like particles (VLPs). These VLPs can be engineered to contain parts of other viruses such as Hepatitis C, HIV or Measles, and have been shown to produce strong antibody responses in mice. Detailed information on the cellular and antibody responses to these VLP vaccines will be aligned with GLP processes to support future clinical trials in man, providing support for the development of urgently needed vaccines against a range of infectious diseases.

Funded Activity Details

Start Date: 01-01-2006

End Date: 01-01-2010

Funding Scheme: Early Career Fellowships

Funding Amount: $421,269.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Biotechnology not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Cellular Immunity | Clinical trials | Hepititis C virus | Preclinical immunogenicity | Vaccines

Related Links